-
Wedbush Maintains ILMN Outperform Rating
Monday, March 21, 2011 - 7:32am | 122Wedbush has issued a report reiterating the Outperform Rating of Illumina (NASDAQ: ILMN). Wedbush writes, "Shares likely to regain mojo over the remainder of 2011, in our opinion. Reaffirming OUTPERFORM. ILMN currently trades at a premium to the peer group on most metrics including PE (43x vs 18x...
-
Illumina Closes $800 Million Convertible Senior Notes
Friday, March 18, 2011 - 4:02pm | 69Illumina, Inc. (NASDAQ: ILMN) today announced the closing of $800 million principal amount of 0.25% Convertible Senior Notes due 2016 through offerings to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In connection with the offering, Illumina...
-
Morgan Stanley Initiates EW Rating For AMAG
Friday, March 18, 2011 - 8:05am | 110Morgan Stanley has issued an Equal-Weight Rating and $17 PT for AMAG Pharmaceuticals (NASDAQ: AMAG). Morgan Stanley writes, "We are assuming coverage of AMAG with an EW rating and $17 PT. Feraheme, an intravenous iron (IVFe) approved in ‘09 to treat iron deficiency anemia (IDA) associated with...
-
Morgan Stanley Initiates EW Rating For AMAG
Friday, March 18, 2011 - 8:03am | 110Morgan Stanley has issued an Equal-Weight Rating and $17 PT for AMAG Pharmaceuticals (NASDAQ: AMAG). Morgan Stanley writes, "We are assuming coverage of AMAG with an EW rating and $17 PT. Feraheme, an intravenous iron (IVFe) approved in ‘09 to treat iron deficiency anemia (IDA) associated with...
-
PURE Bioscience Reports Q2 EPS of $(0.07)
Thursday, March 17, 2011 - 4:08pm | 87PURE Bioscience (NASDAQ: PURE)today reported product revenues for the fiscal second quarter ended January 31, 2011 of $58,400, compared with product revenues of $327,000 in the same quarter of the prior fiscal year. The Company reported a net loss of $2,479,600 or $(0.07) per share for the...
-
Cramer's St. Patrick's Day Picks (PKI, WFC)
Thursday, March 17, 2011 - 2:48pm | 241This afternoon on CNBC, Jim Cramer said that with regard to Perkinelmer Inc. (NYSE: PKI), “it's nice to see a company doing extraordinarily well.” “They do a lot of Chinese water testing, so they're already there,” Cramer said. “They do it all. Whatever' wrong ing the water, they spot it. I bet...
-
Cramer Positive on PerkinElmer (PKI)
Thursday, March 17, 2011 - 2:36pm | 20Jim Cramer just mentioned PerkinElmer (NYSE: PKI) positively on CNBC.
-
J.P. Morgan Maintains Neutral on Medivation (MDVN)
Thursday, March 17, 2011 - 8:37am | 100J.P. Morgan is out with its report today on Medivation (NASDAQ: MDVN), maintaining Neutral. In a note to clients, J.P. Morgan writes, "Our December 2011 price target of $12 is based on our probability-adjusted NPV analysis of MDV3100 and net cash. We assume a 20% probability of success for MDV...
-
Brean Murray Reiterates Sell Rating On MDVN
Thursday, March 17, 2011 - 7:17am | 89Brean Murray, Carret & Co. is reiterating its Sell rating on shares of Medivation, Inc. (NASDAQ: MDVN). “Medivation reported revenue of $16.6 million and EPS of ($0.11), neither of which is all that meaningful at Medivation's present stage,” Brean Murray, Carret & Co. writes. “The revenue...
-
Oppenheimer Initiates SQNM At Perform, $9 PT
Wednesday, March 16, 2011 - 4:47pm | 73Oppenheimer is initiating coverage of Sequenom Inc. (NASDAQ: SQNM) with an Outperform rating and a $9 price target. “Sequenom is a hybrid diagnostics and life science tools company,” Oppenheimer writes. “Revenues are currently derived predominantly from sales of the MassArray system and related...
-
Oppenheimer Initiates AFFX At Perform
Wednesday, March 16, 2011 - 4:44pm | 63Oppenheimer initiating coverage of Affymetrix Inc. (NASDAQ: AFFX) with a Perform rating. “Affymetrix is a life science tools company primarily known for its microarray franchise,” Oppenheimer writes. “Recently, the company has begun a diversification strategy to reduce its reliance on traditional...
-
Oppenheimer Assumes Coverage Of LIFE, ILMN
Wednesday, March 16, 2011 - 4:27pm | 65Oppenheimer is assuming coverage of Life Technologies Corporation (NASDAQ: LIFE) and Illumina Inc. (NASDAQ: ILMN) due to a “reallocation of analyst resources.” “Our estimates, ratings, and price targets remain intact at this time,” Oppenheimer said. Life Technologies closed today at $49.32;...
-
Options Brief: Thermo Fisher Scientific (TMO)
Wednesday, March 16, 2011 - 2:00pm | 87Shares of Thermo Fisher Scientific (NYSE: TMO) are lower on the session by 1.96%, trading at $53.02. Overall put volume is now running at 6.19x the daily average, with 68% of all puts traded being purchases on the offer. 1,522 contracts have traded on the session so far. Thermo Fisher Scientific...
-
AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation
Tuesday, March 15, 2011 - 12:07pm | 115AstraZeneca (NYSE: AZN) today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC). The Phase III clinical programme is designed to...
-
Puts Purchased on Exelixis, Inc. (EXEL)
Tuesday, March 15, 2011 - 11:32am | 138Shares of Exelixis, Inc. (NASDAQ: EXEL) are lower on the session by 1.34%, currently trading at $11.05. The stock has been moving largely higher over the past four months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the name today. A...